TCL1A EXPRESSION IN SPLENIC MARGINAL ZONE LYMPHOMAS (SMZL) AND CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CORELLATION WITH IMMUNOPHENOTYPE, MYD88L265P EXPRESSION AND CLINICAL DATA
(Abstract release date: 05/19/16)
EHA Library. Kalpadakis C. 06/09/16; 134762; PB1862
Assoc. Prof. Christina Kalpadakis
Contributions
Contributions
Abstract
Abstract: PB1862
Type: Publication Only
Background
SMZL and CBL-MZ display significant similarities. TCL1A expression may be a valuable tool for the diagnosis of SMZL. TCL1A has been recently shown to be highly expressed in Waldenstrom macroglobulinemia, although data is limited.
Aims
The aim of the present study was to evaluate TCL1A expression in a series of bone marrow samples involved by SMZL and CBL-MZ and correlate the findings with other immunophenotypical, morphological, and clinical data, as well as with the presence of MYD88 L265P mutation.
Methods
45 patients were retrospectively analyzed: 20 with SMZL and 25 with CBL-MZ. Immunohistochemical staining was performed using the following antibodies: CD5, CD20, Ki67, cyclin D1, TCL1, T-bet, DBA44, CD23, CD27, IRTA1. MYD88 L265P mutation was detected by allele specific PCR.
Results
The main clinical characteristics as well as immunohistochemical and molecular findings are summarized in the table.TCL1A staining was negative in 17/20 cases of SMZL (85%) and 22/25 (88%) cases of CBL-MZ.DNA-44 was positive in 17/24 (71%) of cases in both groups. None case expressed IRTA1. T-bet was positive in 55% and 36% of SMZL and CBL-MZ cases, respectively. No correlation was found between TCL1A and DBA44 expression. Regarding SMZL cases, all TCL1A-positive cases were also positive for CD27. 8/25 (28%)CBL-MZ cases were positive for the presence of MYDL265P mutation. In SMZL cases only 1/11 patient was positive for the presence of MYD88. No correlation was found between TCL1A expression and the presence of MYD88 mutation. None of the mutated cases were TCL1A positive. Among TCL1A-positive SMZL cases, 1/3 presented disease progression with histologic transformation to double-hit lymphoma. All TCL1A-negative SMZL cases were treated with rituximab-monotherapy and are alive without disease.2/3 TCL1A-positive CBL-MZ cases progressed and required therapy due to the presence of cytopenias and one of them died of the disease. None of the TCL1A-negative CBL-MZ cases presented disease progression.
Conclusion
Both SMZL and CBL-MZ display similar pattern of TCL1A, DBA44, IRTA1 and T-bet expression. TCL1A is rarely expressed in SMZL and CBL-MZ cases. No correlation was found between TCL1A and DBA44 expression. No correlation was found between TCL1A and MYDL265P mutate. CD27 and TCL1A were not mutually exclusive. TCL1A expression may be associated with worse outcome, although the number of TCL1A positive cases are small in order to reach safe conclusions.
Session topic: E-poster
Keyword(s): Marginal zone, Splenic marginal zone lymphoma
Type: Publication Only
Background
SMZL and CBL-MZ display significant similarities. TCL1A expression may be a valuable tool for the diagnosis of SMZL. TCL1A has been recently shown to be highly expressed in Waldenstrom macroglobulinemia, although data is limited.
Aims
The aim of the present study was to evaluate TCL1A expression in a series of bone marrow samples involved by SMZL and CBL-MZ and correlate the findings with other immunophenotypical, morphological, and clinical data, as well as with the presence of MYD88 L265P mutation.
Methods
45 patients were retrospectively analyzed: 20 with SMZL and 25 with CBL-MZ. Immunohistochemical staining was performed using the following antibodies: CD5, CD20, Ki67, cyclin D1, TCL1, T-bet, DBA44, CD23, CD27, IRTA1. MYD88 L265P mutation was detected by allele specific PCR.
Results
The main clinical characteristics as well as immunohistochemical and molecular findings are summarized in the table.TCL1A staining was negative in 17/20 cases of SMZL (85%) and 22/25 (88%) cases of CBL-MZ.DNA-44 was positive in 17/24 (71%) of cases in both groups. None case expressed IRTA1. T-bet was positive in 55% and 36% of SMZL and CBL-MZ cases, respectively. No correlation was found between TCL1A and DBA44 expression. Regarding SMZL cases, all TCL1A-positive cases were also positive for CD27. 8/25 (28%)CBL-MZ cases were positive for the presence of MYDL265P mutation. In SMZL cases only 1/11 patient was positive for the presence of MYD88. No correlation was found between TCL1A expression and the presence of MYD88 mutation. None of the mutated cases were TCL1A positive. Among TCL1A-positive SMZL cases, 1/3 presented disease progression with histologic transformation to double-hit lymphoma. All TCL1A-negative SMZL cases were treated with rituximab-monotherapy and are alive without disease.2/3 TCL1A-positive CBL-MZ cases progressed and required therapy due to the presence of cytopenias and one of them died of the disease. None of the TCL1A-negative CBL-MZ cases presented disease progression.
Conclusion
Both SMZL and CBL-MZ display similar pattern of TCL1A, DBA44, IRTA1 and T-bet expression. TCL1A is rarely expressed in SMZL and CBL-MZ cases. No correlation was found between TCL1A and DBA44 expression. No correlation was found between TCL1A and MYDL265P mutate. CD27 and TCL1A were not mutually exclusive. TCL1A expression may be associated with worse outcome, although the number of TCL1A positive cases are small in order to reach safe conclusions.
Session topic: E-poster
Keyword(s): Marginal zone, Splenic marginal zone lymphoma
Abstract: PB1862
Type: Publication Only
Background
SMZL and CBL-MZ display significant similarities. TCL1A expression may be a valuable tool for the diagnosis of SMZL. TCL1A has been recently shown to be highly expressed in Waldenstrom macroglobulinemia, although data is limited.
Aims
The aim of the present study was to evaluate TCL1A expression in a series of bone marrow samples involved by SMZL and CBL-MZ and correlate the findings with other immunophenotypical, morphological, and clinical data, as well as with the presence of MYD88 L265P mutation.
Methods
45 patients were retrospectively analyzed: 20 with SMZL and 25 with CBL-MZ. Immunohistochemical staining was performed using the following antibodies: CD5, CD20, Ki67, cyclin D1, TCL1, T-bet, DBA44, CD23, CD27, IRTA1. MYD88 L265P mutation was detected by allele specific PCR.
Results
The main clinical characteristics as well as immunohistochemical and molecular findings are summarized in the table.TCL1A staining was negative in 17/20 cases of SMZL (85%) and 22/25 (88%) cases of CBL-MZ.DNA-44 was positive in 17/24 (71%) of cases in both groups. None case expressed IRTA1. T-bet was positive in 55% and 36% of SMZL and CBL-MZ cases, respectively. No correlation was found between TCL1A and DBA44 expression. Regarding SMZL cases, all TCL1A-positive cases were also positive for CD27. 8/25 (28%)CBL-MZ cases were positive for the presence of MYDL265P mutation. In SMZL cases only 1/11 patient was positive for the presence of MYD88. No correlation was found between TCL1A expression and the presence of MYD88 mutation. None of the mutated cases were TCL1A positive. Among TCL1A-positive SMZL cases, 1/3 presented disease progression with histologic transformation to double-hit lymphoma. All TCL1A-negative SMZL cases were treated with rituximab-monotherapy and are alive without disease.2/3 TCL1A-positive CBL-MZ cases progressed and required therapy due to the presence of cytopenias and one of them died of the disease. None of the TCL1A-negative CBL-MZ cases presented disease progression.
Conclusion
Both SMZL and CBL-MZ display similar pattern of TCL1A, DBA44, IRTA1 and T-bet expression. TCL1A is rarely expressed in SMZL and CBL-MZ cases. No correlation was found between TCL1A and DBA44 expression. No correlation was found between TCL1A and MYDL265P mutate. CD27 and TCL1A were not mutually exclusive. TCL1A expression may be associated with worse outcome, although the number of TCL1A positive cases are small in order to reach safe conclusions.
Session topic: E-poster
Keyword(s): Marginal zone, Splenic marginal zone lymphoma
Type: Publication Only
Background
SMZL and CBL-MZ display significant similarities. TCL1A expression may be a valuable tool for the diagnosis of SMZL. TCL1A has been recently shown to be highly expressed in Waldenstrom macroglobulinemia, although data is limited.
Aims
The aim of the present study was to evaluate TCL1A expression in a series of bone marrow samples involved by SMZL and CBL-MZ and correlate the findings with other immunophenotypical, morphological, and clinical data, as well as with the presence of MYD88 L265P mutation.
Methods
45 patients were retrospectively analyzed: 20 with SMZL and 25 with CBL-MZ. Immunohistochemical staining was performed using the following antibodies: CD5, CD20, Ki67, cyclin D1, TCL1, T-bet, DBA44, CD23, CD27, IRTA1. MYD88 L265P mutation was detected by allele specific PCR.
Results
The main clinical characteristics as well as immunohistochemical and molecular findings are summarized in the table.TCL1A staining was negative in 17/20 cases of SMZL (85%) and 22/25 (88%) cases of CBL-MZ.DNA-44 was positive in 17/24 (71%) of cases in both groups. None case expressed IRTA1. T-bet was positive in 55% and 36% of SMZL and CBL-MZ cases, respectively. No correlation was found between TCL1A and DBA44 expression. Regarding SMZL cases, all TCL1A-positive cases were also positive for CD27. 8/25 (28%)CBL-MZ cases were positive for the presence of MYDL265P mutation. In SMZL cases only 1/11 patient was positive for the presence of MYD88. No correlation was found between TCL1A expression and the presence of MYD88 mutation. None of the mutated cases were TCL1A positive. Among TCL1A-positive SMZL cases, 1/3 presented disease progression with histologic transformation to double-hit lymphoma. All TCL1A-negative SMZL cases were treated with rituximab-monotherapy and are alive without disease.2/3 TCL1A-positive CBL-MZ cases progressed and required therapy due to the presence of cytopenias and one of them died of the disease. None of the TCL1A-negative CBL-MZ cases presented disease progression.
Conclusion
Both SMZL and CBL-MZ display similar pattern of TCL1A, DBA44, IRTA1 and T-bet expression. TCL1A is rarely expressed in SMZL and CBL-MZ cases. No correlation was found between TCL1A and DBA44 expression. No correlation was found between TCL1A and MYDL265P mutate. CD27 and TCL1A were not mutually exclusive. TCL1A expression may be associated with worse outcome, although the number of TCL1A positive cases are small in order to reach safe conclusions.
Session topic: E-poster
Keyword(s): Marginal zone, Splenic marginal zone lymphoma
{{ help_message }}
{{filter}}